Lupin Ltd

₹ 2,196 0.78%

14 Jan

🔗 Website | BSE: 500257 | NSE: LUPIN

Market Cap1,00,308

Current Price2,196

High / Low2,228

Stock P/E18.8

Book Value596

Dividend Yield0.55

ROCE21.9

ROE17.8

ABOUT

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

Stock Analysis

### Description Lupin Limited is a Mumbai-headquartered pharmaceutical company with a global presence in branded and generic formulations, biotechnology products, and APIs. ### Key Growth Triggers Currently no data available for Key Growth Triggers. ### Order Book Currently no data available for Order Book. ### Key Red Flags Currently no data available for Key Red Flags. ### Key Dates To Watch - Cut-off Date for members: January 09, 2026 - Remote e-voting period: January 15, 2026, to February 13, 2026 - Results submission deadline: On or before February 17, 2026.

Peer Comparison

S.No.	Name	Current Price (Rs.)	Price to Earning	Market Capitalization (Rs.Cr.)	Dividend yield (%)	Net Profit latest quarter (Rs.Cr.)	YOY Quarterly profit growth (%)	Sales latest quarter (Rs.Cr.)	YOY Quarterly sales growth (%)	Return on capital employed (%)	Sales (Rs.Cr.)	OPM (%)	Profit after tax (Rs.Cr.)	Profit after tax latest quarter (Rs.Cr.)	Price to book value	Return on assets (%)	Debt to equity
1.	Sun Pharma.Inds.	1700.70	35.35	408054.90	0.94	3124.95	2.56	14478.31	8.93	20.21	54964.01	30.12	11543.96	3117.95	5.24	12.97	0.07
2.	Divi's Lab.	6355.50	67.89	168718.56	0.47	689.00	35.10	2715.00	16.12	20.44	10029.00	32.37	2485.00	689.00	10.95	13.53	0.01
3.	Torrent Pharma.	4003.70	62.54	135503.40	0.80	591.00	32.49	3302.00	14.30	27.05	12248.00	32.60	2166.53	600.17	16.04	13.26	0.33
4.	Cipla	1434.50	21.30	115874.78	0.91	1353.37	3.73	7589.44	7.64	22.72	28349.57	25.40	5441.14	1351.17	3.52	14.72	0.01
5.	Lupin	2195.90	18.80	100308.45	0.55	1357.35	7.55	4068.28	-0.92	21.91	18470.54	38.24	5335.31	868.74	3.68	14.99	0.04
6.	Dr Reddy's Labs	1186.50	17.16	99028.89	0.67	1336.80	7.28	8828.30	9.83	22.69	34310.00	24.64	5772.20	1347.10	2.75	12.95	0.16
7.	Mankind Pharma	2244.40	52.99	92649.97	0.04	520.18	-22.00	3697.16	20.77	15.98	13545.67	24.12	1748.55	511.51	6.06	8.89	0.55

Quarterly Results

Figures in Cr.

	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	2,829	2,861	2,836	3,496	3,659	4,116	3,396	4,168	4,106	4,208	4,486	5,709	4,068
YOY Sales Growth %	-1.44%	4.73%	-0.67%	27.93%	29.35%	43.85%	19.73%	19.22%	12.21%	2.24%	32.09%	36.97%	-0.92%
Expenses	2,515	2,646	2,574	2,791	2,824	2,898	2,696	2,968	2,991	2,797	2,740	2,979	2,893
Material Cost %	43.74%	41.68%	42.11%	35.65%	33.52%	32.41%	35.88%	30.33%	32.37%	27.47%	26.21%	20.69%	31.2%
Employee Cost %	17.31%	16.68%	16.29%	14.98%	14.54%	12.69%	15.23%	14.13%	14.48%	13.7%	12.32%	11.28%	14.97%
Operating Profit	314	215	262	705	835	1,217	700	1,200	1,115	1,411	1,746	2,730	1,176
OPM %	11%	8%	9%	20%	23%	30%	21%	29%	27%	34%	39%	48%	29%
Other Income	15	17	55	28	26	23	31	38	33	-22	49	54	663
Exceptional items	0	0	0	0	0	0	0	0	0	-77	0	0	593
Other income normal	15	17	55	28	26	23	31	38	33	55	49	54	70
Interest	18	31	29	16	15	11	13	14	18	20	34	19	28
Depreciation	138	134	146	140	149	145	290	141	146	153	208	177	175
Profit before tax	173	67	142	577	696	1,084	428	1,083	984	1,217	1,553	2,588	1,636
Tax %	14%	40%	16%	17%	21%	15%	10%	18%	18%	19%	17%	18%	17%
Net Profit	149	40	119	477	549	916	384	889	808	985	1,291	2,128	1,357
EPS in Rs	3.27	0.89	2.62	10.48	12.05	20.13	8.43	19.5	17.71	21.58	28.28	46.6	29.72

Profit & Loss

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	8,939	9,752	11,344	12,626	10,081	11,356	11,026	11,056	11,772	11,259	14,666	16,968	18,471
Sales Growth %	25.51%	9.1%	16.32%	11.31%	-20.16%	12.66%	-2.91%	0.27%	6.47%	-4.36%	30.27%	15.69%	—
Expenses	6,016	6,375	7,357	8,134	7,992	8,504	9,116	9,012	11,560	10,295	11,216	11,574	11,408
Material Cost %	32.28%	30.87%	28.84%	26.47%	34.47%	34.28%	38.16%	37.83%	37.95%	42.61%	34.26%	29.03%	—
Raw material cost	2,961	3,182	3,444	3,527	3,390	4,040	4,236	4,264	4,710	4,677	5,041	4,964	—
Change in inventory	-76	-171	-173	-185	85	-147	-29	-82	-242	121	-16	-38	—
Manufacturing Cost %	9.74%	10.28%	10.91%	12.39%	15.63%	12.92%	13.83%	13.8%	13.83%	14.24%	11.09%	9.92%	—
Employee Cost %	9.45%	10.79%	10.74%	11.11%	14.3%	13.35%	15.45%	15.34%	16.3%	17.18%	14.29%	13.63%	—
Other Cost %	15.84%	13.43%	14.36%	14.45%	14.88%	14.33%	15.24%	14.55%	30.13%	17.41%	16.83%	15.64%	—
Operating Profit	2,922	3,377	3,987	4,492	2,089	2,853	1,909	2,044	211	964	3,451	5,394	7,062
OPM %	33%	35%	35%	36%	21%	25%	17%	18%	2%	9%	24%	32%	38%
Other Income	405	177	187	82	128	-49	-286	129	215	210	115	176	744
Exceptional items	-9	-3	19	-6	41	-314	-654	54	31	18	29	-33	—
Other income normal	415	180	168	88	87	265	369	75	184	192	86	209	—
Interest	21	5	24	29	33	35	53	41	73	98	56	84	100
Depreciation	168	337	306	366	390	426	519	503	514	548	725	648	712
Profit before tax	3,139	3,212	3,844	4,179	1,794	2,342	1,052	1,630	-162	527	2,785	4,837	6,994
Tax %	26%	25%	26%	25%	25%	34%	31%	23%	17%	19%	16%	18%	—
Net Profit	2,324	2,397	2,831	3,141	1,345	1,539	728	1,259	-189	425	2,326	3,973	5,761
Exceptional items AT	-7	-3	14	-4	31	-205	-426	42	31	14	24	-27	—
Profit excl Excep	2,331	2,400	2,817	3,145	1,314	1,744	1,153	1,217	-219	411	2,302	4,000	—
Profit for PE	2,331	2,400	2,817	3,145	1,314	1,744	1,153	1,217	-219	411	2,302	4,000	—
Profit for EPS	2,324	2,397	2,831	3,141	1,345	1,539	728	1,259	-189	425	2,326	3,973	—
EPS in Rs	51.84	53.34	62.83	69.56	29.74	34.01	16.06	27.74	-4.15	9.35	51.05	87.02	126.18
Dividend Payout %	12%	14%	12%	11%	17%	15%	37%	23%	-96%	43%	16%	14%	—

Balance Sheet

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	90	90	90	90	90	90	91	91	91	91	91	91	91
Reserves	6,889	8,938	11,823	14,690	15,695	17,027	17,383	18,475	18,059	18,321	20,512	24,187	27,133
Borrowings	144	45	392	593	17	6	6	485	951	749	105	250	1,014
Long term Borrowings	24	19	14	9	4	1	0	0	0	0	0	0	0
Short term Borrowings	115	21	373	580	8	2	5	299	790	613	18	0	706
Lease Liabilities	—	—	—	—	—	—	—	—	—	—	—	—	—
Other Borrowings	5	5	5	5	5	4	0	0	0	0	0	0	—
Other Liabilities	1,675	1,935	1,931	2,475	2,879	2,567	3,201	2,808	3,212	3,523	4,215	3,904	4,423
Trade Payables	984	1,042	1,129	1,478	1,428	1,254	1,566	1,196	1,352	1,566	2,036	1,969	2,115
Advance from Customers	39	7	4	4	22	11	13	9	15	9	23	13	—
Other liability items	653	885	798	992	1,429	1,303	1,622	1,602	1,846	1,948	2,156	1,922	2,308
Total Liabilities	8,799	11,008	14,236	17,848	18,681	19,690	20,680	21,859	22,313	22,684	24,923	28,432	32,661
Fixed Assets	2,179	2,036	2,345	3,013	3,341	3,373	3,514	3,639	3,690	4,022	4,113	4,946	4,943
Land	71	105	95	109	186	197	208	211	212	212	175	175	—
Building	745	772	749	1,125	1,184	1,266	1,570	1,737	1,875	1,949	1,846	2,049	—
Plant Machinery	2,052	2,173	1,638	2,156	2,391	2,683	3,128	3,479	3,802	4,200	4,181	4,402	—
Equipments	107	123	78	147	163	178	191	197	201	214	241	279	—
Furniture & fittings	—	—	—	—	—	—	—	—	—	—	—	—	—
Vehicles	5	6	6	7	7	8	27	33	40	49	54	60	—
Intangible Assets	23	31	9	18	322	343	349	367	359	16	16	0	1,155
Other fixed assets	17	21	13	13	17	24	26	36	50	593	960	1,567	—
Gross Block	3,089	3,310	2,649	3,669	4,373	4,808	5,666	6,230	6,705	7,408	7,605	8,673	—
Accumulated Depreciation	910	1,275	304	656	1,032	1,435	2,152	2,591	3,015	3,386	3,492	3,727	—
CWIP	267	490	624	481	1,171	1,199	822	951	947	927	446	278	322
Investments	1,164	3,444	3,741	6,914	5,363	7,388	7,456	9,563	9,511	9,974	11,581	11,955	14,098
Other Assets	5,189	5,038	7,526	7,441	8,806	7,730	8,888	7,706	8,165	7,761	8,783	11,253	13,299
Inventories	1,372	1,740	1,914	2,126	2,180	2,306	2,485	2,708	3,177	3,019	2,969	3,227	3,400
Trade receivables	2,860	2,515	4,545	3,902	4,946	3,724	3,616	3,191	2,722	2,674	3,842	5,664	6,749
Receivables under 6m	—	—	—	—	—	—	—	—	—	—	—	—	—
Receivables over 6m	—	—	—	—	—	—	—	—	—	—	—	—	—
Prow for Doubtful	—	—	—	—	—	—	—	—	—	—	—	—	—
Cash Equivalents	146	59	35	173	111	61	1,306	284	65	101	139	459	378
Loans & Advances	—	—	—	—	—	—	—	—	—	—	—	—	—
Other Assets items	—	—	—	—	—	—	—	—	—	—	—	—	—
Total Assets	8,799	11,008	14,236	17,848	18,681	19,690	20,680	21,859	22,313	22,684	24,923	28,432	32,661

Cash Flows

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	1,528	2,852	917	4,352	209	3,111	2,219	1,570	151	1,794	2,504	2,445
Profit from operations	3,133	3,522	4,222	4,677	2,244	3,000	1,771	2,117	288	1,111	3,556	5,549
Receivables	-1,077	372	-2,072	531	-1,089	1,316	276	407	518	73	-1,311	-1,795
Inventory	-41	-367	-174	-212	-54	-126	-179	-224	-469	158	-158	-303
Payables	117	57	215	356	-41	-182	292	-356	154	215	537	-33
Loans Advances	-40	-10	-18	-18	-11	-6	6	1	-1	-4	0	0
Other WC items	56	76	-241	-1	-350	-79	440	53	-486	368	27	-166
Working capital changes	-985	128	-2,290	657	-1,545	922	835	-118	-285	810	-905	-2,296
Direct taxes	-620	-798	-1,015	-982	-490	-811	-386	-429	148	-127	-147	-808
Cash from Investing Activity	-447	-1,178	-2,629	-1,941	725	-2,865	-740	-2,508	-372	-1,269	-1,599	-1,766
Fixed assets purchased	-394	-507	-753	-963	-910	-971	-518	-520	-597	-575	-699	-1,294
Fixed assets sold	2	2	32	22	1	30	2	2	5	14	9	10
Investments purchased	0	-0	-3	-0	-5,350	-9,136	-14,114	-13,559	-12,736	-12,433	-10,849	-14,970
Investments sold	1	0	4	1	6,945	7,132	14,000	11,507	12,833	12,018	10,514	14,975
Interest received	6	3	1	7	1	38	8	32	23	7	6	73
Redeemp Cnce of Shares	—	—	—	—	—	—	—	—	—	—	—	—
Acquisition of companies	—	—	—	—	—	—	—	—	—	—	—	—
Other investing items	-64	60	-11	2	10	-0	-132	31	101	-300	728	24
Cash from Financing Activity	-844	-221	17	-160	-987	-295	-368	-53	102	-498	-867	-460
Redemption of debentures	—	—	—	—	—	—	—	—	—	—	—	—
Proceeds from borrowings	0	0	356	227	0	0	4	294	492	0	0	0
Repayment of borrowings	-532	-99	-5	-5	-576	-11	-4	-0	-0	-177	-595	-18
Interest paid fin	-22	-6	-15	-18	-18	-16	-21	-7	-51	-73	-29	-49
Dividends paid	-313	-134	-337	-338	-338	-225	-226	-272	-295	-182	-183	-365
Financial liabilities	0	0	0	0	0	0	-80	-78	-59	-68	-74	-68
Other financing items	-2	-23	-36	-69	-69	-46	-47	0	0	0	0	0
Net Cash Flow	237	1,452	-1,696	2,252	-52	-50	1,112	-991	-118	27	38	218

Ratios

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	117	94	146	113	179	120	120	105	84	87	96	122
Inventory Days	174	211	214	232	229	216	216	236	260	230	216	239
Days Payable	124	126	126	161	150	118	136	104	110	119	148	146
Cash Conversion Cycle	166	179	234	184	258	218	199	237	234	197	163	215
Working Capital Days	133	115	169	127	219	171	154	146	124	110	116	153
ROCE %	50%	40%	36%	30%	11%	16%	10%	9%	-1%	3%	14%	22%

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	47.1%	47.08%	47.07%	47.06%	47.04%	47.01%	46.99%	46.96%	46.94%	46.91%	46.9%	46.89%
Anuja Gupta	0.16	0.16	0.16	0.16	0.16	0.16	0.16	0.16	0.16	0.16	0.16	0.16
D B Gupta	—	—	—	—	—	—	—	—	—	—	0.14	0.14
Desh Bandhu Gupta HUF	0.14	0.14	0.14	0.14	0.14	0.14	0.14	0.14	0.14	0.14	—	—
Kavita Gupta	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04
Lupin Investments Private Limited	45.56	45.54	45.53	45.52	45.5	45.47	45.45	45.42	45.41	45.38	45.37	45.36
Manju D Gupta	0.85	0.85	0.85	0.85	0.85	0.85	0.85	0.85	0.85	0.85	0.85	0.85
Manju D Gupta (As a Trustee of Gupta Family Trust)	0	0	0	0	0	0	0	0	0	0	0	0
Neel Deshbandhu Gupta	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Nilesh Gupta	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Richa Gupta	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05
Shefali Nath Gupta	0	0	0	0	0	0	0	0	0	0	0	0
Veda Nilesh Gupta	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02
Vinita Gupta	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07
FIIs	13.98%	13.32%	13.93%	14.99%	16.11%	18.29%	19.32%	21.5%	22.04%	21.46%	21.25%	20.5%
Government Pension Fund Global	1.57	1.57	1.57	1.38	1.12	—	—	—	—	—	—	—
DIIs	29.39%	28.92%	29.08%	29.14%	29.72%	27.76%	26.77%	25.1%	24.73%	25.41%	25.55%	26.56%
Axis Mutual Fund Trustee Limited A/C Axis Mutual F___	—	—	—	—	—	—	—	1.3	1.38	1.54	1.29	—
DSP Tax Saver Fund	1.02	1.02	—	—	—	—	—	—	—	—	—	—
Hdfc Life Insurance Company Limited	1.07	1.59	1.67	1.68	1.48	1.37	1.33	1.38	1.32	1.31	1.31	1.28
Hdfc Trustee Company Ltd_ A/C Hdfc Balanced Advantage Fund	4.05	4.06	3.88	3.68	3.84	3.11	3.6	3.37	3.36	3.22	3.78	4.75
ICICI Prudential Bluechip Fund	5.58	5.74	5.5	5.14	5.25	—	—	—	—	—	—	—
Icici Prudential Value Discovery Fund	—	—	—	—	—	4.31	3.46	2.54	2.61	2.63	3.22	3.24
Life Insurance Corporation of India	8.23	8.23	8.24	8.23	6.14	5.87	5.13	2.89	2.27	2.05	—	—
Mirae Asset Emerging Bluechip Fund	—	—	1.28	1.68	—	—	—	—	—	—	—	—
Mirae Asset Large & Midcap Fund	—	—	—	—	1.76	1.49	1.53	1.02	1.2	1.42	1.52	1.7
NPS Trust - A/c LIC Pension Fund Sch-State Govt	1.3	—	—	—	—	—	—	—	—	—	—	—
Nippon Life India Trustee Ltd-A/C Nippon India Growth Fund	1.85	1.93	1.85	1.77	1.89	1.87	1.86	1.81	1.9	1.88	2.1	2.95
Nps Trust- A/C Hdfc Pension Fund Management Limite___	—	—	—	—	—	—	—	—	1.31	1.42	1.48	1.47
SBI Life Insurance Co_ Ltd_	—	—	—	—	—	—	—	1.04	1.05	1.07	—	—
Sbi Long Term Equity Fund	1.12	1.12	—	1.09	1.23	1.14	1.17	1.6	1.63	1.62	1.72	1.81
Government	0%	0.28%	0.28%	0.28%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0%	0%
Public	9.51%	10.39%	9.62%	8.52%	7.1%	6.93%	6.92%	6.44%	6.27%	6.21%	6.28%	6.06%
NPS Trust - A/c HDFC Pension Fund Management Compa___	—	—	—	1.02	—	—	—	—	—	—	—	—
NPS Trust - A/c LIC Pension Fund Sch-State Govt	—	1.24	1.23	—	—	—	—	—	—	—	—	—
Others	—	—	—	—	—	—	—	—	—	—	—	—
No. of Shareholders	3,60,677	3,48,149	3,22,678	2,89,074	2,81,542	2,80,248	2,88,537	2,79,280	2,81,988	2,83,210	2,86,604	2,80,256

News & Updates

BSE Announcements

Direct from BSE filings, AI summarised

Lupin Limited Announces Postal Ballot for Appointment of Anand Kripalu as Independent Director

14 Jan 2026

Lupin Limited Appoints Anand Kripalu as Independent Director

6 Jan 2026

Lupin Limited Files Quarterly SEBI Compliance Certificate

5 Jan 2026

Lupin Limited Updates VISUfarma B.V. Acquisition Closing Date to February 28, 2026

30 Dec 2025

Lupin Limited Updates VISUfarma B.V. Acquisition Closing Date to February 28, 2026

30 Dec 2025

Other Websites

External media mentions

Pharma Q3: Revlimid Loss Hits US Sales, Domestic Growth Offers Cushion

15 Jan 2026

Delhi HC Restores Diabetes Drug Ban, Broadens Govt Regulatory Power

14 Jan 2026

Expert Trading Calls: Ipca Labs, MTAR, Equitas Lead Jan 12 Stock Ideas

12 Jan 2026

Gland Pharma Surges 5% to 1-Month High on USFDA Eye Drug Approval

8 Jan 2026

Nifty Trades Flat Amid Select Stock Picks: BSE, HCL Tech, Lupin Highlighted

8 Jan 2026

News Articles

Editorial & research coverage

Pharma Q3: Revlimid Loss Hits US Sales, Domestic Growth Offers Cushion

15 Jan 2026

Delhi HC Restores Diabetes Drug Ban, Broadens Govt Regulatory Power

14 Jan 2026

Nifty Trades Flat Amid Select Stock Picks: BSE, HCL Tech, Lupin Highlighted

8 Jan 2026

Indian Markets Flatline; Midcaps Shine as Nifty Holds 26,100

7 Jan 2026

Pharma Stocks Rally to 52-Week Highs, Outperforming Market

7 Jan 2026

Documents

Announcements

Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

18h - Postal ballot to appoint Anand Kripalu (DIN 00118324) as Independent Director Feb 01, 2026–Jan 31, 2031

Announcement under Regulation 30 (LODR)-Change in Directorate

6 Jan - Anand Kripalu appointed independent director effective Feb 1, 2026, five-year term to Jan 31, 2031.

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

5 Jan - Certificate under Reg. 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended on December 31, 2025.

Announcement under Regulation 30 (LODR)-Updates on Acquisition

30 Dec - Lupin's subsidiary Nanomi to acquire VISUfarma B.V.; closing expected by Feb 28, 2026.

Announcement under Regulation 30 (LODR)-Press Release / Media Release

29 Dec - Dec 29, 2025: Lupin gets exclusive India license to Gan & Lee's fortnightly GLP‑1 Bofanglutide.

Annual Reports

FY Financial Year 2025

(from bse)

FY Financial Year 2024

(from bse)

FY Financial Year 2023

(from bse)

FY Financial Year 2022

(from bse)

FY Financial Year 2021

(from bse)

FY Financial Year 2020

(from bse)

FY Financial Year 2019

(from bse)

FY Financial Year 2018

(from bse)

FY Financial Year 2017

(from bse)

FY Financial Year 2016

(from bse)

FY Financial Year 2015

(from bse)

FY Financial Year 2014

(from bse)

FY Financial Year 2013

(from bse)

FY Financial Year 2012

(from bse)

FY Financial Year 2012

(from nse)

Credit Ratings

Rating update

9 Oct 2025 from icra

Rating update

30 Jun 2025 from icra

Rating update

25 Apr 2024 from icra

Rating update

23 Feb 2023 from icra

Rating update

10 Nov 2021 from icra

Rating update

24 Sep 2021 from icra

Concalls

Nov 2025

Transcript PPT

Aug 2025

Transcript PPT

May 2025

Transcript PPT

Feb 2025

Transcript PPT

Nov 2024

Transcript PPT

Aug 2024

Transcript

Aug 2024

Transcript PPT

May 2024

Transcript PPT

Feb 2024

Transcript PPT

Nov 2023

Transcript PPT

Aug 2023

Transcript PPT

May 2023

Transcript PPT

Feb 2023

Transcript PPT

Jan 2023

PPT

Nov 2022

Transcript PPT

Aug 2022

Transcript PPT

May 2022

Transcript PPT

Feb 2022

Transcript PPT

Jan 2022

PPT

Nov 2021

Transcript PPT

Aug 2021

Transcript PPT

May 2021

Transcript PPT

Feb 2021

Transcript PPT

Jan 2021

PPT

Nov 2020

Transcript PPT

Aug 2020

Transcript

Jun 2020

Transcript PPT

Feb 2020

Transcript PPT

Jan 2020

PPT

Nov 2019

Transcript

Nov 2019

Transcript PPT

Aug 2019

PPT

May 2019

PPT

Feb 2019

Transcript PPT

Jan 2019

PPT

Nov 2018

Transcript PPT

Aug 2018

Transcript PPT

Jun 2018

PPT

May 2018

PPT

Feb 2018

PPT

Jan 2018

PPT

Nov 2017

Transcript PPT

Sep 2017

PPT

Aug 2017

PPT

May 2017

PPT

Feb 2017

PPT

Jan 2017

PPT

Nov 2016

PPT

Jun 2016

Transcript

Lupin Ltd

ABOUT

Stock Analysis

Peer Comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

News & Updates

BSE Announcements

Other Websites

News Articles

Documents

Announcements

Annual Reports

Credit Ratings

Concalls